Skip to content
Menu

NeuroSense Therapeutics Ltd. NRSN

Full chart Compare
Set alert

Price alert · NRSN

All alert types
1.69 USD -0.07 (-3.98%)

Regular-session close

1.71 +0.02 +1.18%

After hours · Nov 13, 4:00 PM ET

1.60 Day range 1.78
1.10 52-week range 25.40
YTD
-89.01%
1 year
-90.80%

Fundamental scorecard

5 of 25 checks passed on NRSN’s reported financials

Value: 0/5ValueGrowth: 1/5GrowthProfitability: 0/5ProfitabilityFinancial health: 4/5HealthDividend: 0/5Dividend

5of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Jun 30, 2026.

Value 0 of 5

  • Failed:P/E below its own 5-year median No profit over FY 2025, so no P/E.
  • Failed:P/E under 20 No profit over FY 2025, so no P/E.
  • Failed:Price to sales below its own 5-year median Not enough data to decide.
  • Failed:Price to book below its own 5-year median Shareholders’ equity is negative.
  • Failed:Free cash flow yield above 4% Free cash flow of -7.68M is -239.5% of the market value.

Growth 1 of 5

  • No data:Revenue grew over the last year Not enough data to decide.
  • No data:Revenue grew more than 5% a year over five years Not enough data to decide.
  • Passed:Earnings per share grew over the last year EPS -8.80 against -10.80 in the year before.
  • Failed:Earnings per share grew more than 5% a year over five years EPS -10.20 in FY 2020, -8.80 in FY 2025.
  • No data:Analysts expect higher earnings per share over the next year No analyst estimate.

Profitability 0 of 5

  • Failed:Profitable over the last year Net income of -11.1M over FY 2025.
  • Failed:Profitable in each of the last five fiscal years A profit in 0 of the last 5 fiscal years.
  • Failed:Return on equity above 15% Return on equity of -4635.4%.
  • No data:Net margin above its 5-year average Not enough data to decide.
  • Failed:Free cash flow is at least 80% of net income No profit over FY 2025 to compare with.

Financial health 4 of 5

  • Failed:Short-term assets cover short-term liabilities Short-term assets of 844K against short-term liabilities of 3.00M.
  • Passed:Short-term assets cover long-term liabilities Short-term assets of 844K against long-term liabilities of 0.
  • Passed:Net debt under 40% of equity More cash than debt: 231K of cash against 0 of debt.
  • Passed:Operating cash flow covers at least 20% of debt The company has no debt.
  • Passed:Operating profit covers interest at least 3 times The company has no debt.

Dividend 0 of 5

  • Failed:Pays a dividend No dividend paid.
  • Failed:Yield above 1.5% No dividend paid.
  • Failed:Pays out under 75% of profit No dividend paid.
  • Failed:Covered by free cash flow No dividend paid.
  • Failed:Not cut in the last five fiscal years No dividend paid.

Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.

Included in Essentials and up

Sign in to see Fair value

Discounted cash flow estimates against the price, and the P/E against its industry and sector.

Included in Essentials and up

Sign in to see Head count and owner earnings

Employees by annual report and the cash the business earns for its owners.

Financial position

What NRSN owns and owes, as of Jun 30, 2026

Short term and long term

Balance sheet · 896K of assets

Liabilities exceed assets, so there is no shareholders’ equity to show.

Debt, equity and cash by year

Now: 231K more cash than debt

  • Equity
  • Debt
  • Cash

Fiscal years, then the newest quarter. Cash includes short-term investments.

From the company’s SEC filings.

Cash flow and returns

How NRSN’s profit turns into cash, and what its capital earns

From profit to free cash flow · FY 2025

Returns on capital · FY 2025

  • Benchmark 15%

    -4635.4%

    Return on equity

    Below the 15% mark · Profit per dollar of shareholders’ equity

  • Benchmark 5%

    -406.7%

    Return on assets

    Below the 5% mark · Profit per dollar of everything it owns

From the company’s SEC filings. The tick on each dial is a common rule-of-thumb level, not a target.

Financial health

Altman Z-Score

-123.19 Distress zone

Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.

Piotroski F-Score

1 / 9 Weak

Nine pass/fail tests of profitability, leverage and efficiency.

Rating

D+1 / 5 overall

  • DCF 1
  • Return on Equity 1
  • Return on Assets 1
  • Debt / Equity 1
  • P/E 1
  • P/B 1

Valuation

P/E -1.7×
FY 2019: -18.4×FY 2020: -7.9×FY 2021: -10.7×FY 2022: -1.1×FY 2023: -0.9×FY 2024: -2.2×FY 2025: -1.7×
FY 2019 5y median -1.7× FY 2025
P/S 0.0×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2019 5y median 0.0× FY 2025
P/B -12.6×
FY 2019: 24.0×FY 2020: 33.8×FY 2021: 3.0×FY 2022: 2.5×FY 2023: -6.1×FY 2024: 8.6×FY 2025: -12.6×
FY 2019 5y median 2.5× FY 2025
P/FCF -2.6×
FY 2019: -37.4×FY 2020: -31.7×FY 2021: -17.2×FY 2022: -1.8×FY 2023: -1.3×FY 2024: -2.2×FY 2025: -2.6×
FY 2019 5y median -2.2× FY 2025
EV/EBITDA -1.8×
FY 2019: 1626×FY 2020: -7.6×FY 2021: -5.4×FY 2022: -0.9×FY 2023: -0.9×FY 2024: -1.9×FY 2025: -1.8×
FY 2019 5y median -1.8× FY 2025
EV/Sales 0.0×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: 0.0×FY 2024: 0.0×FY 2025: 0.0×
FY 2019 5y median 0.0× FY 2025
FCF Yield -39.2%
FY 2019: -2.7%FY 2020: -3.2%FY 2021: -5.8%FY 2022: -54.5%FY 2023: -78.3%FY 2024: -45.4%FY 2025: -39.2%
FY 2019 5y median -45.4% FY 2025

Profitability

Gross Margin 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025
ROE 713.1%
FY 2019: -133.7%FY 2020: -429.1%FY 2021: -44.9%FY 2022: -219.6%FY 2023: 574.6%FY 2024: -395.3%FY 2025: 713.1%
FY 2019 5y median -44.9% FY 2025
ROIC 797.5%
FY 2019: -134.5%FY 2020: -438.2%FY 2021: -51.6%FY 2022: -224.1%FY 2023: 5877.6%FY 2024: -372.8%FY 2025: 797.5%
FY 2019 5y median -51.6% FY 2025
ROA -1082.2%
FY 2019: -128.5%FY 2020: -363.0%FY 2021: -35.4%FY 2022: -160.1%FY 2023: -317.3%FY 2024: -223.2%FY 2025: -1082.2%
FY 2019 5y median -223.2% FY 2025

Growth (YoY)

Revenue 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 FY 2025
Operating Income -11.9%
FY 2019: 0.0%FY 2020: -133.8%FY 2021: -93.5%FY 2022: -142.6%FY 2023: 11.1%FY 2024: 17.8%FY 2025: -11.9%
FY 2019 FY 2025
EPS (diluted) 20.0%
FY 2019: 0.0%FY 2020: -131.8%FY 2021: 54.9%FY 2022: -365.2%FY 2023: 22.4%FY 2024: 33.7%FY 2025: 20.0%
FY 2019 FY 2025
Free Cash Flow 24.3%
FY 2019: 0.0%FY 2020: -19.5%FY 2021: -121.0%FY 2022: -392.0%FY 2023: -9.5%FY 2024: -20.9%FY 2025: 24.3%
FY 2019 FY 2025

Financial Health

Current Ratio 0.3×
FY 2019: 24.7×FY 2020: 6.1×FY 2021: 19.1×FY 2022: 4.3×FY 2023: 0.8×FY 2024: 2.2×FY 2025: 0.3×
FY 2019 5y median 2.2× FY 2025
Quick Ratio 0.3×
FY 2019: 24.7×FY 2020: 6.1×FY 2021: 19.4×FY 2022: 4.3×FY 2023: 0.8×FY 2024: 2.2×FY 2025: 0.3×
FY 2019 5y median 2.2× FY 2025
Debt / Equity -0.1×
FY 2019: 0.0×FY 2020: 0.0×FY 2021: 0.0×FY 2022: 0.0×FY 2023: -0.1×FY 2024: 0.0×FY 2025: -0.1×
FY 2019 5y median 0.0× FY 2025
Net Debt / EBITDA -0.0×
FY 2019: -68.8×FY 2020: 0.2×FY 2021: 3.8×FY 2022: 0.3×FY 2023: 0.3×FY 2024: 0.3×FY 2025: -0.0×
FY 2019 5y median 0.3× FY 2025
Interest Coverage 0.0×
FY 2019: -247×FY 2020: 0.0×FY 2021: -4.8×FY 2022: -903×FY 2023: -21.9×FY 2024: -31.8×FY 2025: 0.0×
FY 2019 5y median -21.9× FY 2025

Dividends

Dividend Yield 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2019: 0.0%FY 2020: 0.0%FY 2021: 0.0%FY 2022: 0.0%FY 2023: 0.0%FY 2024: 0.0%FY 2025: 0.0%
FY 2019 5y median 0.0% FY 2025

Annual · latest fiscal year ends 2025-12-31